Treatment of renal transplant recipients with low bone mineral density and vascular calcification: a prospective study of alendronate therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220155

Enrollment

Registered

2013-12-09

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplant recipients for secondary osteoporosis and vascular calcification

Interventions

Intervention type:DRUG Name of intervention:alendronate Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application:ORAL Dose per administration:35 mg Dosing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Kidney transplant recipients for secondary osteoporosis with stable allograft function (defined by serum creatinine < 2.0 mg/dL) for at least 1 year

Exclusion criteria

Exclusion criteria: Patients which are administered bisphosphonate or underwent parathyroidectomy(PTx) within 12 months prior to the informed consent.

Design outcomes

Primary

Measure	Time frame
bone mineral density (BMD) aortic calcification index (ACI)	—

Secondary

Measure	Time frame
bone turnover markers, renal function	—

Countries

Japan

Contacts

Public ContactMasanori Okamoto

Wakayama Medical University

mokamoto@wakayama-med.ac.jp+81-73-441-0639

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026